ReviewFrontiers in cardiovascular medicine2026
Artificial intelligence in cardio-oncology: decoding mechanisms, predicting toxicity, and personalizing cancer therapy.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy-related cardiovascular toxicity (CTR-CVT) threatens the sustainability of oncological advancements, demanding innovative approaches for early risk stratification. This review synthesizes how artificial intelligence (AI) is redefining cardio-oncology through multimodal integration of multi-omics, dynamic imaging, and real-world biosensor data. By decoding novel pathophysiological mechanisms and enabling continuous risk reclassification, AI transcends traditional static paradigms to generate patient-specific toxicity trajectories. Crucially, AI-driven interventions shift clinical practice from reactive monitoring to preemptive cardioprotection. While challenges in data heterogeneity, model interpretability, and equitable implementation persist, emerging solutions like federated learning and explainable AI pave the way for robust clinical translation. We hope that this review will summarize the current state of emerging applications of machine learning and AI in precision medicine predictive modeling, providing direction for AI-enabled precision cardiovascular oncology-ensuring the effectiveness of cancer treatment while safeguarding long-term cardiovascular health through personalized risk mitigation measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.